SCHEMBL8559644

SCHEMBL8559644

Nc1ccc(Sc2ccc3cc(Cl)ccc3n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.53
▸ PDE7A Q13946 3/20 0.42
▸ PDE7B Q9NP56 1/20 0.42
▸ APP P05067 1/20 0.42
▸ BACE1 P56817 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ PLAU P00749 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ LMNA P02545 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CTSD P07339 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ CASP6 P55212 1/20 0.39
▸ KDM1A O60341 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8559109 0.81 HTR3A (0.37) MAPTBACE1TP53SMN1; SMN2CTSD
SCHEMBL27200601 0.79 MAPT (0.49) MAPTPDE7AAPPBACE1CYP3A4
SCHEMBL8567023 0.79 NCF1 (0.56) MAPTAPPCYP3A4MAPK1TP53
SCHEMBL11193963 0.78 MAPT (0.50) MAPTPDE7APDE7BAPPCYP3A4
SCHEMBL3389504 0.78 KDM1A (0.53) MAPTBACE1CYP3A4TSHRMAPK1
SCHEMBL11056189 0.73 LMNA (0.67) MAPTAPPBACE1PLAUTP53
SCHEMBL2130719 0.71 BACE1 (0.72) BACE1PLAUPIK3CG
SCHEMBL23457529 0.71 HTR3A (0.35) BACE1SMN1; SMN2CTSDHPGDPIK3CG
SCHEMBL22926821 0.71 PLAU (0.45) MAPTPDE7ABACE1CYP3A4TSHR
SCHEMBL10647219 0.71 APP (0.56) MAPTAPPMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5814646-A TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS ELI LILLY AND COMPANY (US) 1998-09-29 — — US disclosed
US-5624937-A TREATMENT OF ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1997-04-29 — — US disclosed
Send feedback